JB Pharma, an Indian pharmaceutical company, has entered into ‘Statin’ segment by inking an agreement with Glenmark Pharmaceuticals Ltd to acquire the entire Razel (Rosuvastatin) franchise for India and Nepal region for Rs 313.7 crore.
With this acquisition, JB Pharma will complete its cardiac portfolio making it a leader in this segment, as Razel ranks among the top 10 brands in the Rosuvastatin molecule category in the country. These brands are focused on the cardiac segment in India and Nepal with a total covered market size of Rs 2,444 crore as per IQVIA MAT Oct ’22 numbers.
Commenting on the acquisition, Nikhil Chopra, CEO and Whole Time Director, JB Pharma, said: “We are glad to announce the acquisition of the Razel (Rosuvastatin and combinations) franchise, thereby marking JB’s expansion into Statins, which is the largest therapeutic segment in cardiology.”
He said that with this addition, “We now have established a strong position in statins besides being among the leaders in hypertension and heart failure – all the fastest growing therapeutic indications in cardiology.”
“We see good growth potential from the acquired brands. This acquisition will help us leverage our existing go-to-market model focussed for this segment and further strengthen our chronic portfolio,” he added.